WRITING

Essays from the path.

Long-form pieces on plant medicine, harm reduction, and the questions we should be asking.

  • May 2026 · 11 min read

    Ibogaine is moving into clinical trials. The cardiac questions haven't moved with it.

    An emergency nurse's guide to QT, CYP2D6, and the questions every facilitator and journeyer should be asking.

    In late April 2026, the White House signed an executive order accelerating federal review of psychedelic compounds — naming ibogaine specifically — and the FDA cleared the first US ibogaine clinical trial. The regulatory timeline is moving faster than the cardiac safety conversation. A clinical, harm-reduction look at what the QT interval actually is, why ibogaine prolongs it, who is at higher risk, and the questions every journeyer should bring to a facilitator.

    Read the full piece →
  • May 2026 · 12 min read

    MDMA in the plant medicine community

    What it is, what it isn't, and the questions we should be asking.

    MDMA is showing up everywhere in plant medicine spaces — sandwiched into mushroom journeys, layered into ayahuasca weekends, sold as the heart opener that makes the deeper work possible. Some of it is beautiful. Some of it is dependence dressed up as healing. A balanced, science-sourced look at the pharmacology, the addiction question, the FDA decision, the dangers of mixing, and the patterns to watch for.

    Read the full piece →